177 related articles for article (PubMed ID: 21943035)
1. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Bayas A; Penzien J; Hellwig K
Acta Neurol Scand; 2011 Oct; 124(4):290-2. PubMed ID: 21943035
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment.
Hellwig K; Haghikia A; Gold R
Mult Scler; 2011 Aug; 17(8):958-63. PubMed ID: 21613333
[TBL] [Abstract][Full Text] [Related]
3. Normal outcome of pregnancy with ongoing treatment with natalizumab.
Fagius J; Burman J
Acta Neurol Scand; 2014 Jun; 129(6):e27-9. PubMed ID: 24527849
[TBL] [Abstract][Full Text] [Related]
4. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Henderson CE
Acta Neurol Scand; 2012 Jul; 126(1):e7. PubMed ID: 22671933
[No Abstract] [Full Text] [Related]
5. Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I; Hellwig K; Berthele A; Kümpfel T; Linker RA; Hartung HP; Paul F; Aktas O;
Arch Neurol; 2012 Feb; 69(2):239-45. PubMed ID: 22332191
[TBL] [Abstract][Full Text] [Related]
6. Switching from natalizumab to fingolimod: an observational study.
Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Arnal-Garcia C; García-Montero MR; Málaga I; Millán-Pascual J; Oliva-Nacarino P; Ramió-Torrentà L; Oreja-Guevara C
Eur J Paediatr Neurol; 2013 Jan; 17(1):50-4. PubMed ID: 23021975
[TBL] [Abstract][Full Text] [Related]
8. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.
Papeix C; Depaz R; Tourbah A; Stankoff B; Lubetzki C
Mult Scler; 2011 Dec; 17(12):1520-2. PubMed ID: 21669937
[TBL] [Abstract][Full Text] [Related]
9. [Natalizumab as induction therapy in multiple sclerosis].
Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P
Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463
[TBL] [Abstract][Full Text] [Related]
10. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.
Grimaldi LM; Prosperini L; Vitello G; Borriello G; Fubelli F; Pozzilli C
Mult Scler; 2012 Sep; 18(9):1337-9. PubMed ID: 22389413
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab use during the third trimester of pregnancy.
Haghikia A; Langer-Gould A; Rellensmann G; Schneider H; Tenenbaum T; Elias-Hamp B; Menck S; Zimmermann J; Herbstritt S; Marziniak M; Kümpfel T; Meinl I; Plavina T; Gold R; Hellwig K
JAMA Neurol; 2014 Jul; 71(7):891-5. PubMed ID: 24821217
[TBL] [Abstract][Full Text] [Related]
13. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
16. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
[TBL] [Abstract][Full Text] [Related]
17. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases.
Hoevenaren IA; de Vries LC; Rijnders RJ; Lotgering FK
Acta Neurol Scand; 2011 Jun; 123(6):430-3. PubMed ID: 21492099
[TBL] [Abstract][Full Text] [Related]
18. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
Baumgartner A; Stich O; Rauer S
Int J Neurosci; 2012 Jan; 122(1):35-9. PubMed ID: 21913869
[TBL] [Abstract][Full Text] [Related]
19. Herpes encephalitis during natalizumab treatment in multiple sclerosis.
Kwiatkowski A; Gallois J; Bilbault N; Calais G; Mackowiak A; Hautecoeur P
Mult Scler; 2012 Jun; 18(6):909-11. PubMed ID: 22048950
[TBL] [Abstract][Full Text] [Related]
20. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
